- Conditions
- Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1, de Novo Myelodysplastic Syndrome, High Risk Myelodysplastic Syndrome, Inv(16), Myelodysplastic Syndrome With Excess Blasts, t(16;16), t(8;21), Untreated Adult Acute Myeloid Leukemia
- Interventions
- Cytarabine, Decitabine, Filgrastim-sndz, Fludarabine Phosphate, Gemtuzumab Ozogamicin, Idarubicin, Laboratory Biomarker Analysis
- Drug · Biological · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–71
of 71
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Acute Myeloid Leukemia, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndrome
- Interventions
- Gemtuzumab Ozogamicin, Busulfan, Cyclophosphamide, Thymoglobulin, Tacrolimus, Mycophenolate Mofetil, Methotrexate
- Drug
- Lead sponsor
- New York Medical College
- Other
- Eligibility
- Up to 30 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2013
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Leukemia
- Interventions
- arsenic trioxide, gemtuzumab ozogamicin, mercaptopurine, methotrexate, tretinoin
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2018
- U.S. locations
- 192
- States / cities
- Roseville, California • Sacramento, California • Stanford, California + 139 more
- Conditions
- Relapsed Adult AML
- Interventions
- Gemtuzumab Ozogamicin 3 mg/m^2, Gemtuzumab Ozogamicin 2 mg/m^2, Pracinostat - 45 mg, Pracinostat - 60 mg
- Drug
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Leukemia
- Interventions
- cyclosporine, gemtuzumab ozogamicin
- Drug
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 60 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Acute Myeloid Leukemia
- Interventions
- mitoxantrone + etoposide + gemtuzumab ozogamicin
- Drug
- Lead sponsor
- Robert Redner, MD
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Gemtuzumab Ozogamicin, Venetoclax
- Drug
- Lead sponsor
- John Quigley
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Indianapolis, Indiana • Ann Arbor, Michigan + 1 more
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Fludarabine, Cytarabine, Gemtuzumab Ozogamicin, Azacitidine, Venetoclax
- Drug
- Lead sponsor
- PedAL BCU, LLC
- Other
- Eligibility
- 29 Days to 21 Years
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2031
- U.S. locations
- 45
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Long Beach, California + 40 more
- Conditions
- Acute Promyelocytic Leukemia With PML-RARA
- Interventions
- Arsenic Trioxide, Gemtuzumab Ozogamicin, Laboratory Biomarker Analysis, Tretinoin
- Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 10 Years and older
- Enrollment
- 151 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2027
- U.S. locations
- 5
- States / cities
- Houston, Texas • Nassau Bay, Texas • Sugar Land, Texas + 1 more
- Conditions
- Acute Myeloid Leukemia, AML, Childhood
- Interventions
- Cytarabine, Daunorubicin, Erwinase, Etoposide, Gemtuzumab ozogamicin, Stem cell transplantation (SCT), Sorafenib
- Drug · Procedure
- Lead sponsor
- Emory University
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome
- Interventions
- Mylotarg, Cytarabine
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Acute Myeloid Leukemia, Leukemia, Acute Myeloid, Myeloid Leukemia, Acute, Leukemia, Myeloid, Acute, Acute Myelogenous Leukemia, Leukemia, Acute Myelogenous, Myelogenous Leukemia, Acute, AML, Bone Marrow Transplant
- Interventions
- Iomab-B, Conventional Care, HCT
- Drug · Procedure
- Lead sponsor
- Actinium Pharmaceuticals
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 22
- States / cities
- Gilbert, Arizona • New Haven, Connecticut • Washington D.C., District of Columbia + 18 more
- Conditions
- Leukemia
- Interventions
- chemotherapy, gemtuzumab ozogamicin
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2002
- U.S. locations
- 13
- States / cities
- Tucson, Arizona • Duarte, California • Miami, Florida + 10 more
- Conditions
- ECG, Pharmacokinetics, Safety
- Interventions
- Gemtuzumab Ozogamicin
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 4
- States / cities
- Augusta, Georgia • Greenville, North Carolina
- Conditions
- Acute Myelogenous Leukemia
- Interventions
- Gemtuzumab Ozogamicin, Liposome-encapsulated Daunorubicin-Cytarabine
- Drug
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Orange, California • Sacramento, California + 2 more
- Conditions
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
- Interventions
- Gemtuzumab Ozogamicin, Liposome-encapsulated Daunorubicin-Cytarabine
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Leukemia
- Interventions
- sargramostim, cyclophosphamide, cytarabine, gemtuzumab ozogamicin, liposomal daunorubicin citrate, topotecan hydrochloride
- Biological · Drug
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2007
- U.S. locations
- 62
- States / cities
- Scottsdale, Arizona • Duarte, California • Palo Alto, California + 44 more
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Untreated Adult Acute Myeloid Leukemia
- Interventions
- gemtuzumab ozogamicin, vorinostat, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 4
- States / cities
- Stanford, California • Detroit, Michigan • Winston-Salem, North Carolina + 1 more
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Venetoclax, Gemtuzumab, Ziftomenib
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Leukemia
- Interventions
- ara-C, gemtuzumab ozogamicin
- Drug · Biological
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 17 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2005
- U.S. locations
- 77
- States / cities
- Anniston, Alabama • Birmingham, Alabama • La Jolla, California + 58 more
- Conditions
- Leukemia, Myelodysplastic Syndromes
- Interventions
- arsenic trioxide, gemtuzumab ozogamicin
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Juvenile Myelomonocytic Leukemia
- Interventions
- Fludarabine, Busulfan, GVHD Prophylaxis, Gemtuzumab Ozogamicin, Anti-Thymocyte Globulin, Isotretinoin
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 1 Month to 30 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2020
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Acute Myelogenous Leukemia, Myelodysplastic Syndrome
- Interventions
- Gemtuzumab Ozogamicin
- Drug
- Lead sponsor
- New York Medical College
- Other
- Eligibility
- Up to 25 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2023
- U.S. locations
- 1
- States / cities
- Valhalla, New York